Stock data
| Market cap. | £11.3m |
| Last close | 154.50p |
| High / Low (52 weeks) | 222.5p / 146.0p |
| Stock market listing | AIM |
| Forecast net debt (m) | N/A |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 1.31 | (1.9) | (30.56) |
| Relative * | 6.29 | 6.15 | (23.69) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2009A | 18.3 | 3.3 | 3.0 | 19.7 | 12.6 | 26.1 |
| 2010A | 23.2 | 5.0 | 2.7 | 13.5 | 18.5 | 10.3 |
| 2011E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2012E | N/A | N/A | N/A | N/A | N/A | N/A |
Last updated on 18/04/2012
Latest research
Commercial perfusion
Outlook | Pharmaceutical & Healthcare | 11/05/2010
Reaching profitability
Review | Pharmaceutical & Healthcare | 23/09/2009
New data on LifePort
Update | Pharmaceutical & Healthcare | 25/06/2009
Kidney transport device
Outlook | Pharmaceutical & Healthcare | 06/05/2009
Poised for take off
Company Comment - Initiation of coverage | Pharmaceutical & Healthcare | 12/02/2009
Investment summary
Lifeline Scientific has received regulatory approval to sell its LifePort kidney transporter device in Brazil. Initial orders are being processed. The company expects to make investments this year to expand geographically and develop its liver transporter, and says, on the back of this, operating and product development costs could be well above the levels seen in 2011. It sold 49 LifePort devices last year versus 47 sold in 2010, bringing the total worldwide installed base to 441. Sales could increase next year on the back of new business in the EU, Brazil and maybe China. Our forecasts are under review.
Last updated on 23/04/2012
Industry outlook
The 2009 machine perfusion study showed improved clinical outcomes from the use of the LifePort kidney transporter, and other papers have shown overall cost savings. Lifeline has a high share of the organ static preservation market with its SPS-1 solution.
Last updated on 23/04/2012
Key management
| John Garcia, Chairman |
| David Kravitz, CEO |
| Lisa Kieres, FD |
Company address
| One Pierce Place Suite 475W Itasca IL 60143 United States +1 847 294 0300 View website |
